Gates Foundation ramps up funding to Exscientia in COVID projectThe Bill & Melinda Gates Foundation must have liked what it saw in an initial collaboration with Exscientia Share XGates Foundation ramps up funding to Exscientia in COVID projecthttps://pharmaphorum.com/news/gates-foundation-ramps-up-funding-to-exscientia-in-covid-project/
Merck kicks off oral COVID-19 antiviral filing in CanadaHealth Canada has started a rolling review of Merck & Co’s molnupiravir, an oral antiviral therapy treatment for Share XMerck kicks off oral COVID-19 antiviral filing in Canadahttps://pharmaphorum.com/news/merck-kicks-off-oral-covid-19-antiviral-filing-in-canada/
White House pledges $3 billion war chest for COVID antiviralsThe Biden Administration has said it will allocate $3 billion of its pandemic rescue plan to the development Share XWhite House pledges $3 billion war chest for COVID antiviralshttps://pharmaphorum.com/news/white-house-pledges-3-billion-war-chest-for-covid-antivirals/
Merck nabs $1.2 billion order for oral COVID antiviral from USThe US government has placed an order with Merck & Co to buy 1.7 million courses of its Share XMerck nabs $1.2 billion order for oral COVID antiviral from UShttps://pharmaphorum.com/news/merck-grabs-1-2-billion-order-for-oral-covid-antiviral-from-us/
New UK biotech Inspira uncloaks with deal to develop inhaled COVID therapyUK biotech Inspira Pharmaceuticals has emerged from stealth mode with a deal with Vectura to develop an inhaled Share XNew UK biotech Inspira uncloaks with deal to develop inhaled COVID therapyhttps://pharmaphorum.com/news/new-uk-biotech-inspira-uncloaks-with-deal-to-develop-inhaled-covid-therapy/
ViiV’s Rukobia cleared in EU as rescue HIV therapyThe European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment Share XViiV’s Rukobia cleared in EU as rescue HIV therapyhttps://pharmaphorum.com/news/viivs-rukobia-cleared-in-eu-as-rescue-hiv-therapy/
BioSig abandons COVID-19 drug trial on safety concernsUS biotech BioSig Technologies has abandoned a phase 2 trial of its antiviral drug merimepodib with Gilead’s Veklury Share XBioSig abandons COVID-19 drug trial on safety concernshttps://pharmaphorum.com/news/biosig-abandons-covid-19-drug-trial-on-safety-concerns/
Gilead starts trials of inhaled remdesivir for earlier-stage COVID-19The first healthy volunteers have started to receive doses of Gilead’s inhaled formulation of remdesivir, which it hopes Share XGilead starts trials of inhaled remdesivir for earlier-stage COVID-19https://pharmaphorum.com/news/gilead-starts-trials-of-inhaled-remdesivir-for-earlier-stage-covid-19/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
